Related Experiment Video
Updated: Jan 23, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients
Aurélie Swalduz1,2, Pierre-Jean Souquet3, Maurice Pérol2
1Department of Chest Diseases & Thoracic Oncology, University Hospital of Saint-Étienne, 42270, Saint Priest en Jarez, France.
Abstract:
Aim: We performed a clinical audit of the management of patients with EGFR mutations, 1 year after the introduction of EGFR tyrosine kinase inhibitor (EGFR-TKI) in first-line treatment. Methods: Compliance was defined by tumor molecular profiling for stage IIIB and IV non-small-cell lung cancer and first-line treatment as recommended by the French guidelines. Results: Among the 169 EGFR-mutated patients, compliance was 76.4%. The most common noncompliance criterion was chemotherapy given in first-line treatment instead of EGFR-TKI. No dedicated multidisciplinary meeting and type of institutions were independent unfavorable predictors for compliance. Compliance to guidelines was significantly correlated with time-to-first subsequent treatment improvement (2.5 vs 9.1 months; p < 0.0001). Conclusion: Implementation of new standards of care is challenging. Our results reinforce the role of multidisciplinary meetings to provide a better access to innovating therapeutics.
Insights
Adherence to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) guidelines for non-small cell lung cancer was 76.4%. Multidisciplinary meetings improved guideline compliance and subsequent treatment timelines.
Area of Science:
- Oncology
- Clinical Audit
- Molecular Diagnostics
Background:
- Introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
- Need to assess clinical practice patterns and guideline adherence post-implementation.
Purpose of the Study:
- To conduct a clinical audit evaluating the management of NSCLC patients with EGFR mutations one year after the introduction of first-line EGFR-TKIs.
- To assess compliance with French national guidelines for tumor molecular profiling and first-line treatment selection.
Main Methods:
- Retrospective clinical audit of 169 patients with EGFR-mutated NSCLC (Stage IIIB/IV).
- Compliance defined by adherence to molecular profiling and recommended first-line EGFR-TKI treatment.
- Analysis of factors associated with noncompliance, including multidisciplinary meetings and institutional type.
Main Results:
- Overall compliance with guidelines was 76.4%.
- Chemotherapy use instead of EGFR-TKI was the most frequent noncompliance.
- Lack of multidisciplinary meetings and institutional factors were linked to lower compliance.
- Guideline compliance significantly correlated with improved time to first subsequent treatment (2.5 vs. 9.1 months, p < 0.0001).
Conclusions:
- Implementing new standards of care, such as first-line EGFR-TKIs, presents challenges in clinical practice.
- Multidisciplinary meetings are crucial for improving adherence to treatment guidelines.
- Enhanced multidisciplinary collaboration can facilitate better patient access to innovative therapeutics.
Related Concept Videos
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
IR Frequency Region: Fingerprint Region
Lung Capacity
The Eukaryotic Promoter Region
Molecular Models
Region of Convergence

